Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 20/20 | 0.74 |
| ▸ | MELK | Q14680 | 1/20 | 0.74 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.73 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | BCL6B | Q8N143 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29874222 | 1.00 | BCL6 (0.74) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL23250133 | 1.00 | BCL6 (0.74) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL23267841 | 0.94 | BCL6 (0.73) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL20284584 | 0.92 | BCL6 (0.70) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL23267126 | 0.91 | BCL6 (0.83) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL22421725 | 0.91 | BCL6 (0.76) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL21787647 | 0.91 | BCL6 (0.83) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL20284056 | 0.91 | BCL6 (0.83) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL20267383 | 0.90 | BCL6 (0.74) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL21787553 | 0.90 | BCL6 (0.68) | BCL6MELKNCOR2CHRM4BCL6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| CN-115397821-A | Bifunctional molecules containing an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | BCL6 1/4885MELK 446/4885NCOR2 640/4885 |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | BCL6 1/4885MELK 446/4885NCOR2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.